Genticel recently announced that it has approached Eumedix, a renowned European corporate finance specialist, for strategic advising.
Genticel is a biotechnology company that works in the clinical stages of research while developing groundbreaking immunotherapies for the prevention of types of cancer that are caused by the human papillomavirus (HPV).
“Eumedix assisted Genticel during our IPO in 2014 and we are very pleased to rely again on its expertise in the final stages of acquiring advanced drug development assets with the potential to drive new growth in Genticel,” Benedikt Timmerman, CEO of Genticel, said.
Eumedix will lend its support to Genticel for the evaluation of the company’s strategic options, the focus of which will be on the facilitation of Genticel’s access to innovative drug candidates. The evaluation conducted by Eumedix will be completed simultaneously to an assessment of the company’s current HPV program.
In addition to the Eumedix announcement, Genticel has declared that there are no safety concerns in regard to the ongoing GTL001 Phase II trial. This information is according to the independent Data Safety and Monitoring Board (DSMB). The report of no safety concerns in this trial are important when it comes to Genticel’s collaboration with Serum Institute of India regarding other vaccine applications.
Alerts Sign-up